As the biopharma industry grapples with the uncertain macro environment brought on by the new administration, CEOs, ...

Health and Human Services employees aren’t the only ones out of work. Thousands of private-sector biopharma professionals ...

Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The ...

According to analysts at Jefferies, legislation such as the newly proposed bills that aim to streamline regulatory processes ...

Analysts at William Blair expect drug developers will continue to perform “at least some animal testing” on their investigational products. Though the process to phase out animal testing will begin ...

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

The Fourth Circuit’s ruling follows a Supreme Court verdict that also allowed the Trump administration to move forward with ...

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

Known as the home of big-name companies including Johnson & Johnson, New Jersey has become a destination for more and more ...